Does psychotherapy share common neuronal pathways with psychopharmacology

Deborah C. Escalante

Although multiple interventions exist for major depressive disorder (MDD), only partial response is achieved in many patients and recurrence is common. With monotherapy approximately two-thirds of patients with MDD show a clinical response, but only about one-third achieve remission. Combination therapy has generally been found to be superior compared with single treatment although not all patients require combination therapy (Table).

There are several reasons that combining medication and psychotherapy may enable more effective treatment of MDD.1,2 Given variable response to treatments, combining a medication with psychotherapy increases the likelihood of response to at least one of them. In addition, the additive effects of combined treatment may better address ongoing vulnerability to depression, as found with recurrent depressive episodes, and persistent, adverse residual symptoms.

The treatments can work synergistically: Medication can increase the effectiveness of psychotherapy (eg, through easing problems with concentration and motivation), and psychotherapy provides a means to address adherence problems with medication. Moreover, combined treatment may enable lower medication doses thus having fewer adverse effects; and medication may reduce the need for persistent or more intensive psychotherapy by easing symptoms.

Not all patients require combination therapy to achieve symptom remission or prevent recurrence. Therefore, combination treatments may expose some patients to more treatment than is necessary. Questions of cost effectiveness arise with the greater expense of psychotherapy plus medication, although potential long-term benefits may outweigh the costs.

Another option is to sequence treatments for depression. Begin treatment with pharmacotherapy or psychotherapy, and if the patient does not have an adequate response, add psychotherapy or pharmacotherapy.3 Studies suggest that a switch to or addition of psychotherapy may decrease the risk of depression recurrence.4-6

Determing when to employ combined treatment strategies

Research findings suggest that chronic depression is more responsive to psychotherapy and medication, although dysthymia without accompanying MDD showed no additional value for combined treatment compared with medication alone.7,8 Psychotherapy may be an essential element in the treatment of depressed patients with a history of childhood trauma as well as those with comorbid personality disorder.9,10 In addition to comorbid personality disorder, combination therapy should be considered with other psychiatric comorbidities that are unlikely to respond fully to monotherapy, such as obsessive compulsive disorder, eating disorders, and posttraumatic stress disorder. Clinicians should also consider combined treatment if the patient experiences a high level of suffering and functional impairment and is at risk for suicide.

These recommendations are consistent with the American Psychiatric Association Practice guideline for the treatment of patients with MDD.

Combining a depression-focused psychotherapy and pharmacotherapy may be a useful initial treatment choice for patients with moderate to severe major depressive disorder. Other indications for combined treatment include chronic forms of depression, psychosocial issues, intrapsychic conflict, interpersonal problems, or a co-occurring Axis II disorder. In addition, patients who have had a history of only partial response to adequate trials of single treatment modalities may benefit from combined treatment. Poor adherence with pharmacotherapy may also warrant combined treatment with medications and psychotherapy focused on treatment adherence.11

Discussing the use of combined treatment with patients

The benefits and risks of the various interventions need to be discussed so that patients can be involved in treatment decisions. In explaining the combination of treatments, a metaphor of a river and depression may be helpful.12 The river is viewed as having psychological and/or emotional, biochemical, and environmental tributaries. The river overflowing its banks is seen as equivalent to a depressive disorder. Medication can have an impact on the biochemical contribution, whereas psychotherapy affects the psychological and emotional contributions. The psychiatrist could also explain that the various river tributaries are interconnected; therefore, psychotherapy also has a biochemical impact and medication modulates emotional and psychological factors.

In addition to the river analogy, similarities to treatment with other medical problems can be useful to explain the need for combined treatment. Combining medication and psychotherapy for depression can be compared with combining surgery and physical therapy for orthopedic problems. Similarly, an analogy can be made for combining medication, exercise, and nutritional interventions for diabetes. This perspective emphasizes that, for depression, as with many health conditions, it should not be an either/or between medications and non-medication treatments. This helps to clarify how medication and other forms of intervention can work together to produce a better outcome.

Many factors contribute to patient’s preferences regarding combining medication and psychotherapy, including family, cultural, and personality factors, as well as health belief models. Being able to acknowledge preferences in a nonjudgmental way while providing the rationale for recommending combined treatment, when appropriate, is an important component of dialogue.

Thomas M. Gutheil, MD,13 professor of psychiatry at Harvard, emphasized the concept of “participant prescribing,” in which the clinician collaborates with the patient in considering the potential impact, concerns, and problems with medication in the context of psychotherapy. Such an approach helps to avert potential power struggles involving the physician as the authority pressuring patients to comply with certain treatment, and patients resisting these efforts. An empathic exploration of the patients’ concerns about various treatment interventions will aid with compliance and provide information about psychological factors that may be relevant to symptoms and other life problems.

Considering psychological vulnerabilities to depression

Knowledge of psychological vulnerabilities to depression can aid in addressing problems that can occur in accepting combined treatment. Patients can struggle with low self-esteem, shame, and narcissistic sensitivity that precede or are exacerbated by depression onset. At risk individuals are sensitive to disappointment and rejection, responding with a sense of injury and anger. This anger is often conflicted, triggering feelings of guilt and worthlessness, and it can become directed inward in the form of self-critical thoughts and feelings. Another core dynamic in depression is the patient’s attempt to deal with low self-esteem by a compensatory idealization of self or others. However, this idealization increases the likelihood and intensity of eventual disappointments, worsening depression.

BACA JUGA:   Xenia kollias psychotherapist - psychologist thessaloniki

Patients can experience shame about their depression, and the illness itself tends to exacerbate self-critical tendencies and feelings of being a bad person. Patients may therefore resist treatments if they experience these interventions as further indications that they are indeed defective, as another narcissistic injury. Thus, they may use medication as a resistance to psychotherapy, if they see the need for therapy as shameful, or they may resist medication if they view this need as a source of shame.

Furthermore, patients may idealize one or the other treatment as the answer to depression. Such idealization can lead to significant disappointment when the patient realizes that other problems persist or there is a recurrence of depression. Addressing patient resistance can be valuable, particularly when patients are best served by combination treatment.


“Angela,” a 25-year-old real estate agent, whose depression responded to treatment with sertraline and psychodynamic psychotherapy, experienced a recurrence of depression. She admitted that she had not been taking the medication consistently and the recurrence happened not long after. Further questioning revealed that angela viewed medication as a narcissistic injury, a sign that she was defective in some way.

Her negative feelings about taking antidepressants contributed to her sense of isolation and jealousy, which she often experienced when growing up. During that time she had viewed herself as less wealthy and not as cool as others in her community. She felt her father was uninterested in her and withdrawn, which she ascribed to her being unappealing and unattractive.

Her feelings of inadequacy and defectiveness had recently intensified in the context of difficulties with her career including a lack of sales. These problems with her job and associated painful feelings of inadequacy appeared to trigger resurgences of depressive symptoms.

  1. Kandel ER . Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited. Am J Psychiatry 1999; 156: 505–524.

  2. Linden DEJ . Cerebral mechanisms of learning revealed by functional neuroimaging in humans. In: Kühn R, Menzel R, Menzel W, Ratsch U, Richter MM, Stamatescu I-O (eds). Adaptivity and Learning – An Interdisciplinary Debate. Springer: Heidelberg, 2003 pp 49–57.

  3. Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME et al. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 1998; 84: 1–6.

  4. Hendler T, Goshen E, Tzila Zwas S, Sasson Y, Gal G, Zohar J . Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Res 2003; 124: 87–103.

  5. Dierks T, Linden DEJ, Jandl M, Formisano E, Goebel R, Lanfermann H et al. Activation of Heschl’s Gyrus during auditory hallucinations. Neuron 1999; 22: 615–621.

  6. Beutel ME, Stern E, Silbersweig DA . The emerging dialogue between psychoanalysis and neuroscience: neuroimaging perspectives. J Am Psychoanal Assoc 2003; 51: 773–801.

  7. Linden DEJ, Prvulovic D, Stirn A, Maurer K . Funktionelle Bildgebung und Psychotherapie. In Walter H (ed). Funktionelle Bildgebung in Psychiatrie und Psychotherapie. Methodische Grundlagen und klinische Anwendungen. Schattauer: Stuttgart, 2005 pp 373–382.

  8. Breiter HC, Rauch SL, Kwong KK, Baker JR, Weisskoff RM, Kennedy DN et al. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53: 595–606.

  9. Mataix-Cols D, Cullen S, Lange K, Zelaya F, Andrew C, Amaro E et al. Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers. Biol Psychiatry 2003; 53: 482–493.

  10. Shapira NA, Liu Y, He AG, Bradley MM, Lessig MC, James GA et al. Brain activation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry 2003; 54: 751–756.

  11. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994; 51: 62–70.

  12. McGuire PK, Bench CJ, Frith CD, Marks IM, Fackowiak RS, Dolan RJ . Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994; 164: 459–468.

  13. Rauch SL, Savage CR, Alpert NM, Miguel EC, Baer L, Breiter HC et al. A positron emission tomographic study of simple phobic symptom provocation. Arch Gen Psychiatry 1995; 52: 20–28.

  14. Dilger S, Straube T, Mentzel HJ, Fitzek C, Reichenbach JR, Hecht H et al. Brain activation to phobia-related pictures in spider phobic humans: an event-related functional magnetic resonance imaging study. Neurosci Lett 2003; 348: 29–32.

  15. Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR et al. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 1996; 53: 380–387.

  16. Pissiota A, Frans O, Fernandez M, von Knorring L, Fischer H, Fredrikson M . Neurofunctional correlates of posttraumatic stress disorder: a PET symptom provocation study. Eur Arch Psychiatry Clin Neurosci 2002; 252: 68–75.

  17. Driessen M, Beblo T, Mertens M, Piefke M, Rullkötter N, Silva Saavedra A et al. Different fMRI activation patterns of traumatic memory in borderline personality disorder with and without additional posttraumatic stress disorder. Biol Psychiatry 2004; 55: 603–611.

  18. Bremner JD, Narayan M, Staib LH, Southwick SM, McGlashan T, Charney DS . Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry 1999; 156: 1787–1795.

  19. Shin LM, Orr SP, Carson MA, Rauch SL, Macklin ML, Lasko NB et al. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Arch Gen Psychiatry 2004; 61: 168–176.

  20. Beauregard M, Leroux JM, Bergman S, Arzoumanian Y, Beaudoin G, Bourgouin P et al. The functional neuroanatomy of major depression: an fMRI study using an emotional activation paradigm. NeuroReport 1998; 9: 3253–3258.

  21. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675–682.

  22. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA . Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001; 50: 651–658.

  23. Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS . Can’t shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry 2002; 51: 693–707.

  24. Baxter Jr LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 681–689.

  25. Schwartz JM, Stoessel PW, Baxter Jr LR, Martin KM, Phelps ME . Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53: 109–113.

  26. Nakatani E, Nakgawa A, Ohara Y, Goto S, Uozumi N, Iwakiri M et al. Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder. Psychiatry Res 2003; 124: 113–120.

  27. Schwartz JM . Neuroanatomical aspects of cognitive behavioural therapy response in obsessive-compulsive disorder. An evolving perspective on brain and behaviour. Br J Psychiatry 1998; 173 (Suppl. 35): 38–44.

  28. Saxena S, Brody AL, Schwartz JM, Baxter LR . Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry 1998; 173 (Suppl 35): 26–37.

  29. Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C et al. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry 2005; 57: 901–910.

  30. Paquette V, Levesque J, Mensour B, Leroux JM, Beaudoin G, Bourgouin P et al. ‘Change the mind and you change the brain’: effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 2003; 18: 401–409.

  31. Straube T, Glauer M, Dilger S, Mentzel HJ, Miltner WHR . Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage 2006; 29: 125–135.

  32. Birbaumer N, Grodd W, Diedrich O, Klose U, Erb M, Lotze M et al. fMRI reveals amygdala activation to human faces in social phobics. NeuroReport 1998; 9: 1223–1226.

  33. Stein MB, Goldin PR, Sareen J, Eyler LT, Brown GG . Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 2002; 59: 1027–1034.

  34. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 2002; 59: 425–433.

  35. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728–737.

  36. Navarro V, Gasto C, Lomena F, Mateos JJ, Marcos T, Portella MJ . Normalization of frontal cerebral perfusion in remitted elderly major depression: a 12-month follow-up SPECT study. Neuroimage 2002; 16: 781–787.

  37. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001; 58: 631–640.

  38. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61: 34–41.

  39. Martin SD, Martin E, Rai SS, Richardson MA, Royall R . Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001; 58: 641–648.

  40. American Psychiatric Association Force or DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (DSM-IV-TR®). American Psychiatric Association, 2000.

  41. Thase ME . Neuroimaging profiles and the differential therapies of depression. Arch Gen Psychiatry 2001; 58: 651–653.

  42. Cherry SR, Phelps ME . Imaging brain function with positron emission tomography. In: Toga AW, Mazziotta JC (eds). Brain Mapping. The Methods. Academic Press: San Diego, 1995 pp 191–221.

  43. Drevets WC, Price JL, Simpson Jr JR, Todd RD, Reich T, Vannier M et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386: 824–827.

  44. Drevets WC . Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813–829.

  45. Sheline Y . Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003; 54: 338–352.

  46. Szeszko PR, MacMillan S, McMeniman M, Lorch E, Madden R, Ivey J et al. Amygdala volume reductions in pediatric patients with obsessive-compulsive disorder treated with paroxetine: preliminary findings. Neuropsychopharmacology 2004; 29: 826–832.

  47. Gilbert AR, Moore GJ, Keshavan MS, Paulson LA, Narula V, Mac Master FP et al. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch Gen Psychiatry 2000; 57: 449–456.

  48. Laakso A, Hietala J . PET studies of brain monoamine transporters. Curr Pharmaceut Des 2000; 6: 1611–1623.

  49. Talbot PS, Laruelle M . The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 2002; 12: 503–511.

  50. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB Positron Emission Tomography Study. Am J Psychiatry 2004; 161: 826–835.

  51. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET Imaging Study. Am J Psychiatry 2001; 158: 1843–1849.

  52. Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G et al. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 1995; 100: 247–256.

  53. Kent JM, Coplan JD, Lombardo I, Hwang DR, Huang Y, Mawlawi O et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652. Psychopharmacology 2002; 164: 341–348.

  54. Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowsky N, Riedel M et al. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacol 2005; 15: 521–524.

  55. Baer L . Behavior therapy: endogenous serotonin therapy? J Clin Psychiatry 1996; 57 (Suppl): 33–35.

  56. Ebert D, Feistel H, Kaschka W, Barocka A, Pirner A . Single photon emission computerized tomographic assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation – Preliminary results. Biol Psychiatry 1994; 35: 880–885.

  57. Ebert D, Ebmeier K . The role of the cingulate gyrus in depression: from functional anatomy to neurochemistry. Biol Psychiatry 1996; 39: 1044–1050.

  58. Rainville P, Carrier B, Hofbauer RK, Bushnell MC, Duncan GH . Dissociation of sensory and affective dimensions of pain using hypnotic modulation. Pain 1999; 82: 159–171.

  59. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC . Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 1997; 277: 968–971.

  60. Hofbauer RK, Rainville P, Duncan GH, Bushnell MC . Cortical representation of the sensory dimension of pain. J Neurophysiol 2001; 86: 402–411.

  61. Röder CH, Michal M, Overbeck G, van de Ven V, Linden DEJ . Pain response in depersonalization – a functional imaging study using hypnosis in healthy subjects. Psychother Psychosomatics, in press.

  62. Rainville P, Hofbauer RK, Paus T, Duncan GH, Bushnell MC, Price DD . Cerebral mechanisms of hypnotic induction and suggestion. J Cogn Neurosci 1999; 11: 110–125.

  63. Birbaumer N, Ghanayim N, Hinterberger T, Iversen I, Kotchoubey B, Kuebler A et al. A spelling device for the paralysed. Nature 1999; 398: 297–298.

  64. Weiskopf N, Veit R, Erb M, Mathiak K, Grodd W, Goebel R et al. Physiological self-regulation of regional brain activity using real-time functional magnetic resonance imaging (fMRI): methodology and exemplary data. Neuroimage 2003; 19: 577–586.

  65. deCharms RC, Christoff K, Glover GH, Pauly JM, Whitfield S, Gabrieli JDE . Learned regulation of spatially localized brain activation using real-time fMRI. Neuroimage 2004; 21: 436–443.

  66. deCharms RC, Maeda F, Glover GH, Ludlow D, Pauly JM, Soneji D et al. Control over brain activation and pain learned by using real-time functional MRI. Proc Natl Acad Sci USA 2005; 102: 18626–18631.

  67. van de Ven VG, Formisano E, Prvulovic D, Roeder CH, Linden DEJ . Functional connectivity as revealed by spatial independent component analysis of fMRI measurements during rest. Hum Brain Mapp 2004; 22: 165–178.

  68. Kent JM, Rauch SL . Neuroimaging studies of anxiety disorders. In: Charney DS, Nestler EJ (eds). Neurobiology of Mental Illness, 2nd edn. Oxford University Press: Oxford, UK, 2004 pp 639–660.

  69. Rauch SL, Whalen PJ, Curran T, Shin LM, Coffey BJ, Savage CR et al. Probing striato-thalamic function in obsessive-compulsive disorder and Tourette syndrome using neuroimaging methods. Adv Neurol 2001; 85: 207–224.

  70. Pasupathy A, Miller EK . Different time courses of learning-related activity in the prefrontal cortex and striatum. Nature 2005; 433: 873–876.

  71. Davis M . Functional neuroanatomy of anxiety and fear. In: Charney DS, Nestler EJ (eds). Neurobiology of Mental Illness, 2nd edn. Oxford University Press: Oxford, UK, 2004 pp 584–604.

  72. Goebel R, Roebroeck A, Kim D-S, Formisano E . Investigating directed cortical interactions in time-resolved fMRI data using vector autoregressive modeling and Granger causality mapping. Magn Res Imaging 2003; 21: 1251–1261.

  73. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter Jr LR . Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003; 160: 522–532.

  74. D’Esposito M, Deouell LY, Gazzaley A . Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. Nat Rev Neurosci 2003; 4: 863–872.

  75. Prasko J, Horacek J, Zalesky R, Kopecek M, Novak T, Paskova B et al. The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioural therapy or antidepressants. Neuroendocrinol Lett 2004; 25: 340–348.

Also Read